An observational study of EGFR mutation status by circulating tumor DNA during the osimertinib treatment of lung cancer harboring EGFR activating and T790M mutations.
Latest Information Update: 01 Apr 2022
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Aug 2021 Status changed from recruiting to completed.
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 21 Dec 2016 New trial record